Related Experiment Videos
Pre-Exposure Prophylaxis for HIV: Evidence and Perspectives
Georgios K Nikolopoulos1, Eirini Christaki2, Dimitrios Paraskevis3
1Medical School, University of Cyprus, P.O. Box: 20537, Nicosia, Cyprus.
Current Pharmaceutical Design
|March 31, 2017
Summary
Pre-exposure prophylaxis (PrEP) with antiretrovirals is a promising HIV prevention strategy. Studies show PrEP is effective and safe, with high interest and adherence in ongoing projects.
Area of Science:
- Public Health
- Infectious Diseases
- Pharmacology
Background:
- HIV remains a significant global health challenge.
- Antiretroviral therapy (ART) is effective for treatment and post-exposure prophylaxis.
- Pre-exposure prophylaxis (PrEP) has emerged as a novel prevention method.
Purpose of the Study:
- To review the efficacy, safety, and effectiveness of PrEP.
- To discuss the potential of PrEP as a public health intervention.
- To explore future challenges and perspectives for PrEP implementation.
Main Methods:
- Review of animal studies and human randomized clinical trials.
- Analysis of data from ongoing demonstration projects.
- Examination of cost-effectiveness models for PrEP.
Main Results:
- Antiretrovirals are effective and safe for daily or intermittent PrEP.
- Concerns regarding drug resistance have not been substantiated by current evidence.
- Demonstration projects show high uptake interest and satisfactory adherence to PrEP.
Conclusions:
- PrEP is a viable and promising strategy for HIV prevention.
- PrEP may be cost-effective, particularly for high-risk populations and in high-prevalence settings.
- Further research and strategic implementation are needed to maximize PrEP's public health impact.